Risk Factors for Ventilator-Associated Pneumonia in Patients Ventilated for Non-Pulmonary Conditions: A Prospective Multicenter Cohort Study (PULMIVAP)
Open Access
- 13 October 2026
- journal article
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (11)
Abstract
Background: Ventilator-associated pneumonia (VAP) is a frequent complication of invasive mechanical ventilation (IMV), yet its determinants in patients ventilated for non-pulmonary indications remain poorly characterized. Methods: Data were derived from the PULMIVAP multicenter prospective cohort (ClinicalTrial: NCT04849039), conducted in 8 Northern Italian intensive care units (January 2021–April 2024). All adults receiving IMV for non-pulmonary indications were enrolled if expected to require IMV >48 hours and antibiotic-free for ≥3 days preceding intubation. Clinical and therapeutic data were collected for up to 15 days of IMV; microbiological sampling was performed according to clinical indication. The primary outcome was time to first VAP within 15 days of IMV (VAP15). Associations between baseline characteristics, time-varying exposures, and VAP15 were evaluated. Thirty-day mortality from IMV initiation was a secondary outcome. Results: Among 406 patients, 148 (36%) developed VAP15, at a median of 6 days (IQR 4.0–7.5) with an incidence rate of 43.2 per 1000 ventilator-days at risk (95% confidence intervals [95% CI], 36.4–49.9). Non-neurologic diagnosis (adjusted hazard ratio [aHR] 0.51; 95% CI, 0.31–0.86), female sex (aHR, 0.52; 95% CI, 0.36–0.75), and early antibiotic initiation (days 1–2 of IMV, aHR, 0.65; 95% CI, 0.45–0.93) were independently associated with lower risk of VAP15. Predominant pathogens were Staphylococcus aureus, Klebsiella spp., and Haemophilus influenzae; multidrug-resistant organisms were uncommon. VAP15 showed no competing relationship or significant association with mortality (overall, 20.4%). Conclusions: In patients receiving IMV for non-pulmonary indications, non-neurologic diagnosis, female sex, and early antibiotic exposure were associated with lower observed VAP incidence, though causality cannot be inferred. Risk-stratified prevention strategies warrant further investigation into this population.Keywords
Funding Information
- Ministero della Salute (GR-2018–12365988)
This publication has 28 references indexed in Scilit:
- Risk Factors for Extubation Failure and Prolonged Intubation in Patients With Acute Brain Injury Following Surgery: A Retrospective StudyWorld Journal of Surgery, 2025
- Incidence, microbiology, and mortality of ventilation-associated pneumonia in a large Italian cohort of critically ill patients: results from the PROSAFE projectClinical Microbiology and Infection, 2025
- Ceftriaxone to prevent early ventilator-associated pneumonia in patients with acute brain injury: a multicentre, randomised, double-blind, placebo-controlled, assessor-masked superiority trialThe Lancet Respiratory Medicine, 2024
- Comparison of multiple definitions for ventilator-associated pneumonia in patients requiring mechanical ventilation for non-pulmonary conditions: preliminary data from PULMIVAP, an Italian multi-centre cohort studyJournal of Hospital Infection, 2023
- Extubation in neurocritical care patients: the ENIO international prospective studyIntensive Care Medicine, 2022
- Sex and gender: modifiers of health, disease, and medicineThe Lancet, 2020
- Ventilator-associated pneumonia in adults: a narrative reviewIntensive Care Medicine, 2020
- Efficacy of antibiotic prophylaxis against ventilator-associated pneumoniaJournal of Hospital Infection, 2019
- Central nervous system injury-induced immune deficiency syndromeNature Reviews Neuroscience, 2005
- Antibiotic prophylaxis of early onset pneumonia in critically ill comatose patients. A randomized studyIntensive Care Medicine, 2005